

ESMO PRECEPTORSHIP LUGANO SWITZERLAND 11-12 JULY 2024

Co-Chairs

Ilaria Colombo, Switzerland Isabelle L. Ray-Coquard, France



ESMO PRECEPTORSHIP PROGRAMME UTERINE CANCER

Multidisciplinary management, standards of care, therapeutic targets and future perspectives

Lugano, Switzerland 11-12 July 2024

CO-CHAIRS

Ilaria Colombo, Switzerland Isabelle L. Ray-Coguard, France **SPEAKERS**

Nicole Concin, Austria
Jean Emmanuel Kurtz, France
Domenica Lorusso, Italy
Sven Mahner, Germany
Xavier Matias-Guiu, Spain
Mansoor R. Mirza, Denmark
Ana Oaknin, Spain

LEARNING OBJECTIVES

- To learn about the fundamentals of diagnosis and staging of endometrial cancer
- To understand the importance of pathological and molecular characterization of endometrial cancer
- To understand the multidisciplinary treatment of endometrial cancer
- To learn about the recent advances in the systemic treatment of endometrial cancer and how to implement them in clinical practice
- To learn about novel targets and agents under investigation in endometrial cancer
- To learn the principles of diagnosis and treatment of uterine sarcoma

ACCREDITATION

The programme of this event has been accredited with 10 ESMO-MORA category 1 points.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from





ORGANISATION AND CONTACTS

ESMO Head Office Education Department Via Ginevra 4, 6900 Lugano Switzerland

Email: courses@esmo.org

www.esmo.org



Thursday, 11 July 2024

09:00-09:15	Welcome and introduction	Ilaria Colombo, CH
15'		Isabelle L. Ray-Coquard, FR
09:15-10:30	SESSION 1	
75 '	Diagnosis and pathology of endometrial cancer Pathology and molecular classification of endometrial cancer	Xavier Matias-Guiu, ES
30'		Nicole Concin, AT
	The new FIGO staging 2023	
15'	Q&A	All
10:30-11:00	Coffee break	
11:00-13:00 120'	SESSION 2 Treatment of disease limited to the uterus	
20'	Complex questions for surgery for newly diagnosed endometrial cancer including role of SLN	Sven Mahner, DE
20'	Adjuvant radiation treatment: Who, when and what?	Mansoor R. Mirza, DK
20'	Adjuvant systemic treatment: Who, when and what?	Ana Oaknin, ES
15'	Q&A	AII
45'	Participants clinical case discussion (3x15')	Faculty
13:00-14:00	Lunch	
14:00-16:00 120'	SESSION 3 Treatment of recurrent-metastatic endometrial cancer – part 1	
20'	The revolution of immunotherapy in endometrial cancer	Ana Oaknin, ES
20'	Combinations of anti-PD-L1 and chemotherapy or TKI in endometrial cancer	Mansoor R. Mirza, DK
20'	Predictive biomarkers in endometrial cancer	Domenica Lorusso, IT
15'	Q&A	All
45'	Participants clinical case discussion (3x15')	Faculty
16:00-16:30	Coffee break	
16:30-18:00 90'	SESSION 3 Treatment of recurrent-metastatic endometrial cancer – part 2	
20'	PRO and QoL: How to manage	Jean Emmanuel Kurtz, FR
20'	New agents on the horizon: ADC and beyond	Domenica Lorusso, IT
20'	Management of immune-related and TKI toxicities	Ilaria Colombo, CH
15'	A&D	All
15'	Participants clinical case discussion (1x15')	Faculty
19:30	Dinner	

Friday, 12 July 2024

09:00-10:35	SESSION 4	
95'	Special situations	
20'	Fertility-sparing approach	Sven Mahner, DE
20'	Rare histological subtypes: Carcinosarcoma	Isabelle L. Ray-Coquard, FR
20'	Hormonal therapy in endometrial cancer: Single agent or combination?	Ilaria Colombo, CH
20'	How to manage old and frail patients?	Jean Emmanuel Kurtz, FR
15'	Q&A	All
10:35-11:05	Coffee break	
11:05-12:35 90'	SESSION 5 Uterine sarcoma	
20'	Diagnosis and surgical treatment of uterine sarcoma	Nicole Concin, AT
20'	Diagnosis and surgical treatment of uterine sarcoma Pathology of uterine sarcoma	Nicole Concin, AT Xavier Mathias-Guiu, ES
20'	Pathology of uterine sarcoma	Xavier Mathias-Guiu, ES
20'	Pathology of uterine sarcoma Systemic treatment of uterine sarcoma	Xavier Mathias-Guiu, ES Isabelle L. Ray-Coquard, FR
20' 20' 15'	Pathology of uterine sarcoma Systemic treatment of uterine sarcoma Q&A	Xavier Mathias-Guiu, ES Isabelle L. Ray-Coquard, FR All

Note: Each 15-minute slot for clinical case discussion includes a 7' case presentation and an 8' Q&A / panel discussion